Cargando…

Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect

BACKGROUND: The vast majority of patients with cholangiocarcinoma (CC) have advanced disease at diagnosis and are candidates for palliative treatment only. The robustness of the randomized controlled trials regarding the treatment of CC are assessed. METHODS: A systematic review of all randomized co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horesh, Nir, Bomze, David, Lim, Chetana, Markel, Gal, Meirson, Tomer, Azoulay, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745612/ https://www.ncbi.nlm.nih.gov/pubmed/36523938 http://dx.doi.org/10.21037/hbsn-21-118

Ejemplares similares

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer
por: Meirson, Tomer, et al.
Publicado: (2023)

Assessment of Median and Mean Survival Time in Cancer Clinical Trials
por: Das, Ananya, et al.
Publicado: (2023)

Trends in Women’s Leadership of Oncology Clinical Trials
por: Waldhorn, Ithai, et al.
Publicado: (2022)

Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

Associating liver partition and portal vein ligation or combined transarterial chemo-embolisation and portal vein embolisation for staged hepatectomy for HBV-related hepatocellular carcinoma
por: Gavriilidis, Paschalis, et al.
Publicado: (2023)

Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers
por: Han, Kyunghwa, et al.
Publicado: (2022)

How Robust are the Evidences that Formulate Surviving Sepsis Guidelines? An Analysis of Fragility and Reverse Fragility of Randomized Controlled Trials that were Referred in these Guidelines
por: Choupoo, Nang S, et al.
Publicado: (2021)

Robustness and Fragility in Immunosenescence
por: Stromberg, Sean P, et al.
Publicado: (2006)

Estimation of Heterogeneous Restricted Mean Survival Time Using Random Forest
por: Liu, Mingyang, et al.
Publicado: (2021)

Restricted mean survival time regression model with time‐dependent covariates
por: Zhang, Chengfeng, et al.
Publicado: (2022)

Omnibus test for restricted mean survival time based on influence function
por: Gu, Jiaqi, et al.
Publicado: (2023)

Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data
por: Huang, Qiao, et al.
Publicado: (2022)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Optimized inferences of finite population mean using robust parameters in systematic sampling
por: Shaheen, Nazia, et al.
Publicado: (2023)

On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve
por: Eng, Kevin H., et al.
Publicado: (2015)

Why restricted mean survival time methods are especially useful for non-inferiority trials
por: Quartagno, Matteo, et al.
Publicado: (2021)

Analyzing differences between restricted mean survival time curves using pseudo-values
por: Ambrogi, Federico, et al.
Publicado: (2022)

Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators
por: Nemes, Szilárd, et al.
Publicado: (2022)

Survival benefits of surgical resection in recurrent cholangiocarcinoma
por: Song, Sun Choon, et al.
Publicado: (2011)

Impact of postoperative complications on long-term survival following surgery for T4 colorectal cancer
por: Osseis, Michael, et al.
Publicado: (2018)

Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models
por: Mozumder, Sarwar I., et al.
Publicado: (2021)

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
por: Karrison, Theodore, et al.
Publicado: (2018)

Restricted Mean Survival Time in Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure
por: Shi, Sandra, et al.
Publicado: (2020)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

Resilience, Fragility, and Robustness: Cities and COVID-19
por: Hunter, Michael
Publicado: (2021)

Extrahepatic cholangiocarcinoma with prolonged survival: a case report
por: Al-Zahir, Mohammed Z., et al.
Publicado: (2017)

Serum albumin predicts survival in patients with hilar cholangiocarcinoma
por: Waghray, Abhijeet, et al.
Publicado: (2017)

Osteopenia Is Associated with Shorter Survival in Patients with Intrahepatic Cholangiocarcinoma
por: Miki, Atsushi, et al.
Publicado: (2023)

Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival
por: Thakral, Nimish, et al.
Publicado: (2023)

Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia
por: Kim, Dae Hyun, et al.
Publicado: (2021)

Optimal two-stage designs based on restricted mean survival time for a single-arm study
por: Shan, Guogen
Publicado: (2021)

Analysis of the Single Ventricle Reconstruction Trial Using Restricted Mean Survival Time and Shunt Type Received
por: Dolgner, Stephen J., et al.
Publicado: (2022)

Nomograms for predicting overall survival and cancer-specific survival in patients with surgically resected intrahepatic cholangiocarcinoma
por: Ma, Kexin, et al.
Publicado: (2019)

MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients
por: Zhuang, Liping, et al.
Publicado: (2021)

Robust Universal Inference
por: Painsky, Amichai, et al.
Publicado: (2021)

An in silico analysis of robust but fragile gene regulation links enhancer length to robustness
por: Barr, Kenneth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_95108k15pgmvbqlvq9odljifsl